Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parenteral Nutrition Associated Liver Disease Clear all
Completed Phase 4 Interventional Results available

Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease

NCT00862446
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease
Interventions
Omegaven
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 24 Months
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 8, 2026, 5:26 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children

NCT02925520
View directory record Official record
Conditions
Parenteral Nutrition-Associated Liver Disease
Interventions
Omegaven
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
4 Weeks to 5 Years
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

NCT02010034
View directory record Official record
Conditions
Liver Disease, Impaired Liver Function, Parenteral Nutrition Associated Liver Disease
Interventions
Omegaven
Drug
Lead sponsor
Children's Medical Center Dallas
Other
Eligibility
2 Months to 10 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Not applicable Interventional Results available

Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates

NCT01050660
View directory record Official record
Conditions
Parenteral Nutrition-Associated Liver Disease
Interventions
Intravenous fat emulsion, Restriction of intravenous fat emulsion to 1 gm/kg/d
Other
Lead sponsor
Yale University
Other
Eligibility
12 Hours to 48 Hours
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Compassionate Use of Omegaven in Children

NCT02370251
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease

NCT04697888
View directory record Official record
Conditions
Parenteral Nutrition-related Hepatitis
Interventions
Omegaven
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

NCT02357576
View directory record Official record
Conditions
Cholestasis
Interventions
Intralipid 20% I.V. Fat Emulsion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 1 Year
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 8, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional

Total Parenteral Nutrition-Associated Liver Disease

NCT00031135
View directory record Official record
Conditions
Liver Diseases
Interventions
Choline Chloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 8, 2026, 5:26 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease

NCT01297933
View directory record Official record
Conditions
Cholestasis, Short Bowel Syndrome
Interventions
Omegaven
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 8, 2026, 5:26 AM EDT
Withdrawn Not applicable Interventional

Compassionate Use of Omegaven IV Fat Emulsion

NCT01323907
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Sivan Kinberg
Other
Eligibility
2 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cholestasis Reversal: Efficacy of IV Fish Oil

NCT00910104
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome, Gastrointestinal Disease
Interventions
Omegaven®
Drug
Lead sponsor
Mark Puder
Other
Eligibility
Up to 17 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 8, 2026, 5:26 AM EDT
Approved For Marketing No phase listed Expanded access

Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants

NCT02534077
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven, Omegaven
Dietary Supplement · Drug
Lead sponsor
Pediatrix
Other
Eligibility
14 Days to 2 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 8, 2026, 5:26 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

NCT02328768
View directory record Official record
Conditions
Total Parenteral Nutrition-Induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 8, 2026, 5:26 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease

NCT01739517
View directory record Official record
Conditions
Short Bowel Syndrome, Cholestasis
Interventions
Omegaven Therapy
Drug
Lead sponsor
Amarnath, Rathna, M.D.
Individual
Eligibility
Up to 1 Year
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

NCT00826020
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
Interventions
Omegaven™
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

NCT04555044
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
0 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • New Haven, Connecticut • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 8, 2026, 5:26 AM EDT
Terminated Phase 4 Interventional Results available

Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders

NCT01373918
View directory record Official record
Conditions
Cholestasis
Interventions
Intralipid
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Minute to 5 Days
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 8, 2026, 5:26 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

NCT01191177
View directory record Official record
Conditions
Liver Disease, Short Bowel Syndrome
Interventions
Lovaza (omega-3-acid ethyl ester), Corn oil
Drug · Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 3 Interventional

Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children

NCT01194063
View directory record Official record
Conditions
Cholestasis
Interventions
Omega-3 fish oil lipid emulsion
Drug
Lead sponsor
Kapiolani Medical Center For Women & Children
Other
Eligibility
Up to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 8, 2026, 5:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis

NCT01601652
View directory record Official record
Conditions
Parenteral Nutrition Associated Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Arthur J De Lorimier
Other
Eligibility
Up to 1 Year
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 8, 2026, 5:26 AM EDT
Not listed Not applicable Interventional

Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation

NCT01157780
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease
Interventions
Lovaza (fish oil)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
1 Day to 1 Year
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 8, 2026, 5:26 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

NCT02929303
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 17 Years
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 8, 2026, 5:26 AM EDT
Completed No phase listed Observational

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

NCT05011370
View directory record Official record
Conditions
Intestinal Failure-associated Liver Disease
Interventions
Not listed
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 8, 2026, 5:26 AM EDT